NEW YORK, Aug. 13, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, Aug. 8, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, Aug. 3, 2025 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, July 28, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

LOS ANGELES, July 28, 2025 /PRNewswire/ -- News provided by DJS Law Group LLP The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws. 

The investigation centers on whether the Company made false and/or misleading statements or failed to disclose material information relevant to investors. On February 5, 2025, Grizzly Research released a report titled: "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud." The report asserts that the Company's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics" allegedly designed to manipulate Medicaid and Medicare programs to artificially boost revenue. It further claims that "testimonies from former employees and pending litigation indicate GeneDx inflated earnings through the unlawful practice of 'code stacking,'" which "allows billing for services that fail to meet the appropriate standards." The report also alleges that "CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting, without participating in open market acquisitions," a "pattern suggest[ing] insider awareness of a looming threat likely to affect the business." 

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. GeneDx is the subject of a report published by Grizzly Research on February 5, 2025, titled: "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud." The report claims that the Company's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to inflate revenue artificially." The report alleges that, "testimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as 'code stacking,'" which "enables the company to bill insurance providers for services that do not meet the required criteria." The report also claims that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases," a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company."

LOS ANGELES, July 22, 2025 /PRNewswire/ -- The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws. 

The investigation centers on whether the Company made false and/or misleading statements or failed to disclose material information relevant to investors. On February 5, 2025, Grizzly Research released a report titled: "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud." The report asserts that the Company's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics" allegedly designed to manipulate Medicaid and Medicare programs to artificially boost revenue. It further claims that "testimonies from former employees and pending litigation indicate GeneDx inflated earnings through the unlawful practice of 'code stacking,'" which "allows billing for services that fail to meet the appropriate standards." The report also alleges that "CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting, without participating in open market acquisitions," a "pattern suggest[ing] insider awareness of a looming threat likely to affect the business." 

NEW YORK, July 21, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

SAN FRANCISCO, July 21, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis. Current shareholders are encouraged to contact the firm.

On June 23, 2025, Judge Vernon D. Oliver of the U.S. District Court for the District of Connecticut ruled that a securities fraud lawsuit against GeneDx, its CEO, and former company executives could move forward. The lawsuit alleges that between January 2022 and August 2022, GeneDx (then named Sema4 Holdings Corp.) misled investors by falsely overstating the capabilities, potential, and commercial viability of Centrellis. These statements allegedly caused GeneDx's stock to trade at artificially inflated prices. Judge Oliver found that the complaint sufficiently alleged that the defendants made false and misleading statements regarding Centrellis with an intent to defraud. During this period, various company insiders sold significant amounts of GeneDx stock. After the truth came out in August 2022 that GeneDx was significantly shifting its core R&D strategy and business model, its President was resigning, and the company was cutting 13% of its workforce, GeneDx's stock price fell 33%.

NEW YORK, July 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, July 10, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, June 23, 2025 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

NEW YORK, June 18, 2025 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. GeneDx is the subject of a report published by Grizzly Research on February 5, 2025, titled: "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud." The report claims that the Company's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to inflate revenue artificially." The report alleges that, "testimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as 'code stacking,'" which "enables the company to bill insurance providers for services that do not meet the required criteria." The report also claims that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases," a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company."

NEWTOWN, Pa., June 13, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving GeneDx Holdings Corp. ("GeneDx") (NASDAQ: WGS), resulting from allegations of providing potentially misleading business information to the investing public.

If you have information that could assist in the GeneDx investigation, or if you are a GeneDx investor who suffered a loss and would like to learn more, you can provide your information HERE.

LOS ANGELES, June 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. GeneDx is the subject of a report published by Grizzly Research on February 5, 2025, titled: "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud." The report claims that the Company's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to inflate revenue artificially." The report alleges that, "testimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as 'code stacking,'" which "enables the company to bill insurance providers for services that do not meet the required criteria." The report also claims that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases," a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company."

NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.